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Cerebral salt wasting is characterized by inappropriate natriuresis and volume con-
traction with associated cerebral pathology. It is distinct from the syndrome of in-
appropriate antidiuretic hormone secretion, which is characterized by inappropri-
ate retention of free water. We report a patient with a porencephalic cyst who 
developed cerebral salt wasting. His initial treatment was supplementation of wa-
ter and salt, which did not improve natriuresis or volume contraction. Fludrocorti-
sone administration effectively managed the cerebral salt wasting.
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INTRODUCTION
Hyponatremia is a common complication of surgery and intracranial afflictions in-
cluding injury, tumor, infection, and stroke.1 Neurological dysfunction resulting 
from cerebral edema is the principal manifestation of hyponatremia. The causes of 
hyponatremia should be evaluated in order to distinguish cerebral salt wasting 
(CSW) from syndrome of inappropriate secretion of antidiuretic hormone (SI-
ADH), since the treatments for the two conditions are very different.1,2 CSW is de-
fined as the renal loss of sodium leading to hyponatremia and extracellular fluid 
volume loss.3 Water and salt supplementation is the primary therapy for CSW, 
whereas water restriction is the primary treatment for SIADH.4 In the literature, it 
has been noted that mineralocorticoid administration is also of benefit in CSW cas-
es.5-10 In the present case, a 17-year-old male patient was diagnosed with CSW and 
was managed effectively with fludrocortisone.
CASE REPORT
A 17-year-old boy was admitted to our hospital with the chief complaint of poor 
oral intake and general weakness on admission. He had been previously admitted 
at seven months of age for delayed development, increased head circumference, 
and the inability to make eye contact. Computed tomography at that time revealed 
a porencephalic cyst in the left parieto-occipital and right frontal area, agenesis of Min Jeong Choi, et al.
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from the laboratory test were as follows: antidiuretic hor-
mone (ADH) level of 5.55 pg/mL, renin level of 3.48 ng/mL/
hr, aldosterone level of 154.2 pg/mL, and a cortisol level of 
164.94 ng/mL. Renal ultrasonography was performed, and 
both kidneys did not show any abnormal findings. We then 
started fludrocortisone 2.5 µg/kg every 12 hours for two 
days, but the patient did not respond to the treatment. His 
blood pressure increased to 111/81 mm Hg, and his heart 
rate was stabilized at 95/min. His serum sodium level fur-
ther decreased to 130 mEq/L, while his chloride level de-
creased to 94 mEq/L, his osmolality to 270 mOsm/kg, and 
his urine sodium level to 62 mEq/L. The fludrocortisone 
dose was then increased to 3.75 µg/kg every 12 hours. Urine 
output, urine sodium, and serum sodium levels were im-
proved. After administration of fludrocortisone for five days, 
the patient’s serum sodium level returned to 141 mEq/L, 
while his urine sodium returned to 75 mEq/L, specific gravi-
ty to 1.015, urine osmolality to 501 mOsm/L, and serum os-
molality to 287 mOsm/L (Fig. 2). The patient’s serum blood 
urea nitrogen level thereafter was 10.2 mg/dL, and his creati-
nine level was 0.53 mg/dL. The patient was discharged with 
instructions to continue the medication. 
DISCUSSION
CSW is characterized by hyponatremia, excessive natriure-
sis, as well as volume depletion and generally occurs in pa-
tients with cerebral injury, tumor, infection or stroke.1 Water 
and salt replacement is the primary management for CSW, 
and the mechanism and treatment thereof are completely dis-
tinct from those of SIADH.3 An incorrect diagnosis can lead 
to inappropriate fluid restriction which may worsen the hy-
povolemia. Clinicians must distinguish CSW from SIADH 
by reviewing the clinical features and laboratory findings 
the corpus callosum, and absence of a septum pellucidum 
(Fig. 1). Electroencephalography illustrated an extremely 
dynamic background voltage suppression in the left hemi-
sphere. Cysto-parietal shunt surgery was performed, and 
anticonvulsant medications were prescribed due to a diag-
nosis of Lennox-Gastaut syndrome. Approximately 5 
months prior to the presently reported admission, he was 
admitted to our hospital with the same symptoms and re-
covered after fluid replacement. On his most recent admis-
sion, the chief complaint was poor oral intake and general 
weakness. His lips and tongue were dried because he had 
little oral intake of food and fluid for 15 days. His serum so-
dium level was 131 mEq/L, potassium was 3.3 mEq/L, 
chloride was 91 mEq/L, urine sodium was 87 mEq/L, and 
his urine specific gravity was 1.025. The serum blood urea 
nitrogen level was 57.2 mg/dL, uric acid was 5.6 mg/dL, 
and creatinine was 1.28 mg/dL. Initial vital signs showed a 
blood pressure of 95/62 mm Hg, heart rate of 136/min, and 
a urine output of 3.1 mL/kg/hr. This volume was replaced 
with intravenous fluid containing sodium chloride. Howev-
er, excessive urine output continued and increased up to 5.1 
mL/kg/hr. Although the urine sodium level and volume 
were not normalized, his serum sodium level increased to 
134 mEq/L after sodium chloride infusion. Hormone levels 
Fig. 1. The computed tomography shows a porencephalic cyst in the left 
parieto-occipital and right frontal areas, showing the inserted cysto-pari-
etal shunt. 
Fig. 2. (A) Changes in serum Na level following fludrocortisone use (mmol/L). (B) Changes in random urine Na level following fludrocorti-
sone use (mmol/L). Na, sodium.
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requirements in the first few months of life, usually 0.1-0.3 
mg daily in two divided doses but occasionally up to 0.4 
mg daily, and often require sodium supplementation (sodi-
um chloride, 1-3 g) in addition to the mineralocorticoid.3 
Older infants and children are typically maintained with a 
0.05-0.1 mg dose of fludrocortisones.3 Our patient demon-
strated that fludrocortisone administration was effective for 
CSW treatment and refractory hyponatremia after intracra-
nial surgery. 
CSW is generally induced by surgery or infection and 
our patient’s CSW was due to a porencephalic cyst. CSW 
was diagnosed in the present case by elevated urine osmo-
lality and a history of intracranial disease. In addition, our 
patient had normal blood pressure, implying relatively nor-
mal effective circulating volume (ECV); however, ECV is 
often low in such cases, causing low blood pressure. 
Considering the potential adverse effects of fludrocorti-
sone, we initiated treatment with a low dose of 2.5 µg/kg 
twice a day. With no improvement observed over two days, 
we increased the fludrocortisone dose from 2.5 µg/kg to 3.75 
µg/kg twice a day, which effectively corrected the hyponatre-
mia. Fludrocortisone was used for three days after discharge, 
(Table 1). The key feature of CSW is a negative sodium bal-
ance, resulting in hyponatremia and extracellular fluid vol-
ume contraction.4 In contrast, SIADH involves inappropriate 
secretion of ADH or increased renal sensitivity to ADH, 
leading to renal conservation of water and euvolemic or hy-
pervolemic hyponatremia.5,7 Proper replacement of urine 
salt and water using 0.9% or 3% sodium chloride is the sa-
lient treatment for CSW.5 The clinical and laboratory status 
of patients with CSW may continue to be poor in spite of 
replacement of urine salt and water. 
The lack of a response to hypertonic saline led us to try 
treatment with fludrocortisone. The administration of fludro-
cortisone to manage CSW was firstly reported in the 1980s 
in adults with head injury and in isolated cases.10 Use in pe-
diatric cases has been reported sporadically (Table 2). 
Fludrocortisone is a synthetic corticosteroid with moder-
ate glucocorticoid potency and substantial mineralocorti-
coid potency.1 It is primarily used to replace the missing 
hormone aldosterone in various forms of adrenal insuffi-
ciencies including Addison’s disease and the classic salt 
wasting form of congenital adrenal hyperplasia.
Infants with CSW may have very high mineralocorticoid 
Table 1. Differential Diagnoses between SIADH and CSW
5
Clinical findings CSW SIADH
Clinical dehydration Present Absent
Plasma Na concentration Severe decreased Moderate decreased
Plasma uric acid Decreased Decreased
Plasma BUN Increased Normal
Urine Na concentration More increased Variable
Urine flow rate More increased Decreased
Plasma ANP concentration Increased Increased
Plasma renin activity Decreased Decreased
Treatment Saline Water restriction
Na, sodium; BUN, blood urea nitrogen; ANP, atrial natriuretic peptide; CSW, cerebral salt wasting; SIADH, syndrome of inappropriate secretion of antidi-
uretic hormone.      
Table 2. Previous Reports of Children with CSW Who Were Successfully Treated with Fludrocortisone
Case  Age 
(months) Sex
Serum Na 
(mmol/L)
Urinary Na 
(mmol/L)
Urine volume
(mL/kg/hr) ADH
(pg/mL)
Renin
(ng/mL/hr)
Pre Post Pre Post Pre Post aldosterone
(pmol/L)
1. Ozdemir, et al.
5   34 boy 124 146 13.8   3.8 5.9
2. Nagotkar, et al.
9   72 girl 109 141 146   10   7 <2
3. Taplin, et al.
3 120 girl 124 136 269 105
    5 girl 116 145   67   5-6    <32
<40
144 girl 121 Normal 330   54   6.9 <32
<40
Na, sodium; ADH, antidiuretic hormone; CSW, cerebral salt wasting.Min Jeong Choi, et al.
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4. Betjes MG. Hyponatremia in acute brain disease: the cerebral salt 
wasting syndrome. Eur J Intern Med 2002;13:9-14.
5. Ozdemir H, Aycan Z, Degerliyurt A, Metin A. The treatment of 
cerebral salt wasting with fludrocortisone in a child with lissen-
cephaly. Turk Neurosurg 2010;20:100-2.
6. Hegde RM. Cerebral salt wasting syndrome: a case report. Crit 
Care Resusc 1999;1:180-3.
7. Kinik ST, Kandemir N, Baykan A, Akalan N, Yordam N. Fludro-
cortisone treatment in a child with severe cerebral salt wasting. 
Pediatr Neurosurg 2001;35:216-9.
8. Sakarcan A, Bocchini J Jr. The role of fludrocortisone in a child 
with cerebral salt wasting. Pediatr Nephrol 1998;12:769-71.
9. Nagotkar L, Shanbag P, Dasarwar N. Cerebral salt wasting syn-
drome following neurosurgical intervention in tuberculous menin-
gitis. Indian Pediatr 2008;45:598-601.
10. Ishikawa SE, Saito T, Kaneko K, Okada K, Kuzuya T. Hyponatre-
mia responsive to fludrocortisone acetate in elderly patients after 
head injury. Ann Intern Med 1987;106:187-91.
and follow-up at outpatient department was planned. How-
ever, the patient was lost to follow up. Although fludrocorti-
sone has some adverse effects including sodium and water 
retention, hypokalemia, and high blood pressure, it can be 
considered as an appropriate alternative treatment in cases of 
CSW, similar to the case presented herein.
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